BIGPRO (biguanides and the prevention of the risk of obesity): study design. A randomized trial of metformin versus placebo in the correction of the metabolic abnormalities associated with insulin resistance
Abstract
There seems to be a cluster of potentially atherogenic and diabetogenic abnormalities in subjects with central adiposity (high waist to hip ratio) and insulin resistance. To test whether reversing insulin resistance could lead to decreased vascular and diabetic risks, a trial using a drug to complement life-style modification measures is necessary. BIGPRO trial proposes to examine the efficacy of metformin, along with diet and exercise advice, in reducing over one year the metabolic abnormalities encountered in non-diabetic subjects with central adiposity. BIGPRO is designed as a randomized double blind one-year trial of metformin (2 tabs/d, i.e. 1,700 mg/d) versus matching placebo (2 tabs/d). Men aged 40-55 years, with a waist to hip ratio greater than or equal to 0.95 and women aged 45-65 years with a waist to hip ratio greater than or equal to 0.80, are eligible to enter the trial, unless they have diabetes, cardiovascular disease, kidney dysfunction, serious illness, or are receiving extensive medical treatment. Between the two treatment groups the changes in the following endpoints will be compared after one year study: waist to hip ratio, blood pressure, blood lipids, glucose, insulin, fibrinolytic activity. At least 400 subjects are expected to complete the trial. The recruitment and follow-up will be distributed among 33 medical centers from various University Hospitals in France. If metformin proves to be effective in reducing the metabolic abnormalities associated…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 400 participants or records.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.